Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M109,830Revenue $M21,662Net Margin (%)32.0Altman Z-Score2.6
Enterprise Value $M110,471EPS $8.4Operating Margin %39.1Piotroski F-Score8
P/E(ttm)17.4Beneish M-Score-2.6Pre-tax Margin (%)36.8Higher ROA y-yY
Price/Book3.910-y EBITDA Growth Rate %11.2Quick Ratio5.1Cash flow > EarningsY
Price/Sales5.25-y EBITDA Growth Rate %10.4Current Ratio5.4Lower Leverage y-yY
Price/Free Cash Flow12.9y-y EBITDA Growth Rate %26.9ROA % (ttm)9.8Higher Current Ratio y-yY
Dividend Yield %2.2PEG1.7ROE % (ttm)25.6Less Shares Outstanding y-yY
Payout Ratio %36.0Shares Outstanding M754ROIC % (ttm)25.3Gross Margin Increase y-yY

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNVanguard Health Care Fund 2015-12-31 Reduce-0.05%$141.22 - $164.58
($157.65)
$ 145.60-8%Reduce -3.25%5,398,985
AMGNMario Gabelli 2015-12-31 Reduce$141.22 - $164.58
($157.65)
$ 145.60-8%Reduce -3.39%39,175
AMGNKen Fisher 2015-12-31 Add$141.22 - $164.58
($157.46)
$ 145.60-8%Add 2.07%136,400
AMGNJoel Greenblatt 2015-09-30 Reduce-0.07%$132.24 - $176.59
($157.63)
$ 145.60-8%Reduce -11.55%406,106
AMGNFirst Eagle Investment 2015-09-30 Add0.04%$132.24 - $176.59
($157.63)
$ 145.60-8%Add 22.77%551,600
AMGNKen Fisher 2015-09-30 Reduce-0.01%$132.24 - $176.59
($157.63)
$ 145.60-8%Reduce -13.84%133,632
AMGNMario Gabelli 2015-09-30 Reduce$132.24 - $176.59
($157.63)
$ 145.60-8%Reduce -0.06%40,550
AMGNDodge & Cox 2015-09-30 Reduce$132.24 - $176.59
($157.63)
$ 145.60-8%Reduce -4.84%48,344
AMGNRuane Cunniff 2015-09-30 Add$132.24 - $176.59
($157.63)
$ 145.60-8%Add 24.74%2,017
AMGNGeorge Soros 2015-09-30 Buy $132.24 - $176.59
($157.63)
$ 145.60-8%New holding2,100
AMGNJoel Greenblatt 2015-06-30 Add0.19%$151.6 - $169.17
($160.19)
$ 145.60-9%Add 48.52%459,125
AMGNFirst Eagle Investment 2015-06-30 Reduce-0.02%$151.6 - $169.17
($160.19)
$ 145.60-9%Reduce -9.71%449,294
AMGNMario Gabelli 2015-06-30 Add$151.6 - $169.17
($160.19)
$ 145.60-9%Add 1.48%40,575
AMGNKen Fisher 2015-06-30 Reduce$151.6 - $169.17
($160.19)
$ 145.60-9%Reduce -0.97%155,101
AMGNDodge & Cox 2015-06-30 Reduce$151.6 - $169.17
($160.19)
$ 145.60-9%Reduce -7.13%50,804
AMGNJoel Greenblatt 2015-03-31 Add0.37%$150.01 - $170.1
($157.49)
$ 145.60-8%Add 2874.44%309,134
AMGNFirst Eagle Investment 2015-03-31 Reduce-0.06%$150.01 - $170.1
($157.49)
$ 145.60-8%Reduce -23.66%497,622
AMGNDodge & Cox 2015-03-31 Reduce$150.01 - $170.1
($157.49)
$ 145.60-8%Reduce -17.65%54,704
AMGNMario Gabelli 2015-03-31 Add$150.01 - $170.1
($157.49)
$ 145.60-8%Add 1.23%39,985
AMGNKen Fisher 2015-03-31 Add$150.01 - $170.1
($157.49)
$ 145.60-8%Add 1.41%156,623
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
de Carbonnel FrancoisDirector 2015-08-31Sell5,000$153.84-6.94view
Hassan FredDirector 2015-08-19Buy3,010$166.63-14.09view
PELHAM JUDITH CDirector 2015-07-31Sell5,035$180.4-20.64view
Patton Cynthia MSVP & CCO 2015-06-02Sell4,530$157.06-8.85view
Balachandran MadhavanEVP, Operations 2015-05-07Sell21,750$157.87-9.32view
Tross Stuart ASVP, Human Resources 2015-04-23Sell3,012$169.31-15.45view
Harper Sean EEVP, Research & Development 2015-04-22Sell28,000$171.58-16.56view
Tross Stuart ASVP, Human Resources 2015-03-03Sell4,415$157.74-9.24view
BALTIMORE DAVIDDirector 2015-03-02Sell3,647$158.76-9.83view
Bradway Robert AChairman, CEO and President 2015-02-11Sell22,000$152.69-6.24view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

News about AMGN:

Articles On GuruFocus.com
Plenty of Opportunity to Buy Individual Stocks: John Buckingham Feb 02 2016 
Alan Fournier Sells GM, Buys Molson Coors Brewing Jan 03 2016 
Analyzing Amgen's Dividend Hike Dec 20 2015 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
PRIMECAP Sells Stake in Technology Company Nov 16 2015 
Loeb, Ackman's Portfolios Post Losses for Year as Top Bets Fall Oct 16 2015 
10 Best Stocks for Value Investors This Week - Sept. 26 Sep 26 2015 
Activist Hedge Fund Manager Dan Loeb Decreases Position in Leading Biotech Company Sep 24 2015 
The Best Companies of the Pharmaceuticals Industry – August 2015 Aug 18 2015 
Perrigo Company Is Strong But Overvalued Jul 15 2015 

More From Other Websites
Biotech ETFs Slide as Stocks Report Mixed Q4 Results Feb 09 2016
What Investors Can Expect from Healthcare Sector Companies Feb 09 2016
#1 Rated Biotech Analyst on the Sell-Off Feb 08 2016
3 Biotech Stocks to Turn the Tide This Earnings Season Feb 08 2016
Avoid biotech until elections? Analyst's view Feb 08 2016
Regeneron: It's the Eylea Outlook That Matters Feb 08 2016
UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's Feb 08 2016
UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's Feb 08 2016
UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's Feb 08 2016
Amgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference Feb 05 2016
LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut Feb 05 2016
Amgen's Blincyto and Repatha Positive in Phase III Studies Feb 05 2016
Leerink Is Back On Board The Biotech Train Feb 05 2016
Generous Dividend Yields And Long Term Optimism: Are Amgen And Apple Smart Investments? Feb 05 2016
[$$] 3 Earnings Dynamos That Are Lighting Up the Street Feb 05 2016
Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With... Feb 04 2016
Workday Snatches Amgen Exec as First CIO Feb 04 2016
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In... Feb 04 2016
It’s Time to Buy This Biotech Gem Feb 04 2016
7 Cash-Rich Stocks to Buy Now Feb 04 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK